Evidence map›Paper›PMID 38742151›Full record

ArticleJournal of bone oncology2024

FBXO22 is a potential therapeutic target for recurrent chondrosarcoma.

Baoquan Xin, Hui Chen, Zhi Zhu, Qiujing Guan, Guangjian Bai, Cheng Yang, WeiWei Zou, Xin Gao, Lei Li, Tielong Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of bone oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Cellular crosstalk in the bone marrow niche.Journal of translational medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Baoquan XinSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200003, China.
Hui ChenJoint Center for Translational Medicine, Shanghai Fifth People's Hospital, Fudan University and School of Life Science, East China Normal University, Shanghai, 200241, China.
Zhi ZhuDepartment of Pathology, Changzheng Hospital, Navy Medical University, No. 415 Fengyang Road, Shanghai, 200003, China.
Qiujing GuanShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, China.
Guangjian BaiSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200003, China.
Cheng YangDepartment of Orthopaedic Oncology, Changzheng Hospital, Navy Medical University, No. 415 Fengyang Road, Shanghai, 200003, China.
WeiWei ZouDepartment of Medical Imaging, Changzheng Hospital, Navy Medical University, No. 415 Fengyang Road, Shanghai, 200003, China.
Xin GaoDepartment of Orthopaedic Oncology, Changzheng Hospital, Navy Medical University, No. 415 Fengyang Road, Shanghai, 200003, China.
Lei LiJoint Center for Translational Medicine, Shanghai Fifth People's Hospital, Fudan University and School of Life Science, East China Normal University, Shanghai, 200241, China.
Tielong LiuDepartment of Orthopaedic Oncology, Changzheng Hospital, Navy Medical University, No. 415 Fengyang Road, Shanghai, 200003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chondrosarcoma (CHS) is a malignant bone tumor with insensitivity to both radiotherapy and chemotherapy, and a high recurrence rate. However, the latent mechanism of recurrent CHS (Re-CHS) remains elusive. Here, we discovered that FBXO22 was highly expressed in clinical samples of Re-CHS. FBXO22 played a significant role in various cancers. However, the role of FBXO22 in Re-CHS remained unclear. Our research demonstrated that suppressing FBXO22 abated the proliferation and migration of CHS cells and facilitated their apoptosis. In addition, suppressing FBXO22 raised the expression of PD-L1 in Re-CHS. All these findings provide new evidence for using FBXO22 and PD-L1 as combined targets to prevent and treat Re-CHS, which may prove to be a novel strategy for immunotherapy of CHS, especially Re-CHS.

Indexed as

Bone tumorChondrosarcomaPD-L1RecurrenceTherapeutic target

Identifiers

PMID38742151
PMCPMC11089373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.